Zobrazeno 1 - 4
of 4
pro vyhledávání: '"David R. Muccino"'
Autor:
David R. Muccino, Alyn H. Morice, Surinder S. Birring, Peter V. Dicpinigaitis, Ian D. Pavord, Christopher Assaid, Huub Jan Kleijn, Azher Hussain, Carmen La Rosa, Lorcan McGarvey, Jaclyn A. Smith
Publikováno v:
ERJ Open Research, Vol 6, Iss 4 (2020)
Background We present study designs, dose selection and preliminary patient characteristics from two phase 3 clinical trials of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough (RCC) or unexplained chronic cough (UCC). Methods COUG
Externí odkaz:
https://doaj.org/article/797aecd766a64455a4cd9c812cd2c339
Autor:
Surinder S Birring, Peter V Dicpinigaitis, Jaclyn A Smith, Alyn H. Morice, Lorcan P. McGarvey, Ian D Pavord, Allison Martin Nguyen, Jonathan Schelfhout, Qing Li, Beata Iskold, Stuart A Green, George Philip, David R. Muccino, Carmen La Rosa
Publikováno v:
American Journal of Respiratory and Critical Care Medicine.
Autor:
Lorcan P McGarvey, Surinder S Birring, Alyn H Morice, Peter V Dicpinigaitis, Ian D Pavord, Jonathan Schelfhout, Allison Martin Nguyen, Qing Li, Anjela Tzontcheva, Beata Iskold, Stuart A Green, Carmen La Rosa, David R Muccino, Jaclyn A Smith
Publikováno v:
COUGH-1 and COUGH-2 Investigators 2022, ' Efficacy and safety of gefapixant, a P2X 3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials ', The Lancet, vol. 399, no. 10328, pp. 909-923 . https://doi.org/10.1016/S0140-6736(21)02348-5
Background: Gefapixant is an oral P2X3 receptor antagonist that has previously shown efficacy and safety in refractory chronic cough and unexplained chronic cough. We therefore aim to confirm the efficacy and safety of gefapixant in participants with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::838940d35f61d2058207e771121821c3
https://pure.qub.ac.uk/en/publications/0b9c7e74-db7c-4e53-a26c-74130e9737ca
https://pure.qub.ac.uk/en/publications/0b9c7e74-db7c-4e53-a26c-74130e9737ca
Autor:
Lorcan P, McGarvey, Surinder S, Birring, Alyn H, Morice, Peter V, Dicpinigaitis, Ian D, Pavord, Jonathan, Schelfhout, Allison Martin, Nguyen, Qing, Li, Anjela, Tzontcheva, Beata, Iskold, Stuart A, Green, Carmen La, Rosa, David R, Muccino, Jaclyn A, Smith
Publikováno v:
Lancet (London, England). 399(10328)
Gefapixant is an oral P2XCOUGH-1 and COUGH-2 were both double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials. COUGH-1 was done in 156 sites in 17 countries and COUGH-2 in 175 sites in 20 countries. We enrolled participants who